ASND: Ascendis Pharma A/S Stocks News on April 3, 2025

ASND

MT Newswires

2 days ago

Ascendis Pharma Files New Drug Application for Achondroplasia Medication

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

ASND

GlobeNewswire

2 days ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

ASND

Zacks

16 days ago

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Exploring US High Growth Tech Stocks In March 2025

ASND

Simply Wall St.

a month ago

Exploring US High Growth Tech Stocks In March 2025

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

ASND

GlobeNewswire

a month ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

ASND

Simply Wall St.

2 months ago

Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Ascendis Pharma Full Year 2024 Earnings: Beats Expectations

ASND

Simply Wall St.

2 months ago

Ascendis Pharma Full Year 2024 Earnings: Beats Expectations

ASND

GuruFocus.com

2 months ago

Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

ASND

Benzinga

2 months ago

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

ASND

MT Newswires

2 months ago

Ascendis Pharma Allocates $25 Million for Share Repurchases, Net Settlement of RSUs

ASND

MT Newswires

2 months ago

Ascendis Pharma Q4 Loss Narrows, Revenue Rises -- Shares Up After Hours

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

ASND

GlobeNewswire

2 months ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

ASND

GlobeNewswire

2 months ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

ASND

GlobeNewswire

2 months ago

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Alibaba Cloud integrates DeepSeek’s AI models

ASND

Verdict

2 months ago

Alibaba Cloud integrates DeepSeek’s AI models

Exploring High Growth Tech Stocks In January 2025

ASND

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks In January 2025

ASND

Insider Monkey

2 months ago

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

ASND

MT Newswires

3 months ago

BioMarin Pharmaceutical Sues Ascendis Pharma for Alleged Patent Infringement in Germany

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

ASND

GlobeNewswire

3 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

ASND

GlobeNewswire

3 months ago

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

ASND

Zacks

3 months ago

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

ASND

GlobeNewswire

3 months ago

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk

ASND

TipRanks

4 months ago

Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

ASND

GlobeNewswire

4 months ago

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

ASND

MT Newswires

4 months ago

Ascendis Pharma's Supplemental BLA for Adult Growth Hormone Deficiency Drug Accepted by FDA

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

ASND

GlobeNewswire

4 months ago

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Exploring Three High Growth Tech Stocks in the United States

ASND

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks in the United States

Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia

ASND

Pharmaceutical Technology

4 months ago

Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia

ASND

MT Newswires

5 months ago

Ascendis Pharma Q3 Loss Narrows, Revenue Rises

Ascendis Pharma Reports Third Quarter 2024 Financial Results

ASND

GlobeNewswire

5 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

ASND

GlobeNewswire

5 months ago

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

High Growth Tech Stocks In The United States To Watch

ASND

Simply Wall St.

5 months ago

High Growth Tech Stocks In The United States To Watch

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

ASND

Pharmaceutical Technology

5 months ago

Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA

Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology

ASND

GuruFocus.com

5 months ago

Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology

Ascendis Pharma and Novo Nordisk Join Forces

ASND

TipRanks

5 months ago

Ascendis Pharma and Novo Nordisk Join Forces

Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform

ASND

TipRanks

5 months ago

Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform

Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug

ASND

Quartz

5 months ago

Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

ASND

Benzinga

5 months ago

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

ASND

MT Newswires

5 months ago

Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

ASND

GlobeNewswire

5 months ago

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

Ascendis Pharma submits sBLA for growth hormone deficiency therapy

ASND

Pharmaceutical Technology

6 months ago

Ascendis Pharma submits sBLA for growth hormone deficiency therapy

High Growth Tech Stocks To Watch In October 2024

ASND

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In October 2024

ASND

MT Newswires

6 months ago

Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

ASND

GlobeNewswire

6 months ago

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

ASND

GlobeNewswire

6 months ago

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

ASND

Benzinga

6 months ago

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

ASND

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Premarket Friday

ASND

MT Newswires

6 months ago

Ascendis Pharma Prices Offering of American Depositary Shares

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

ASND

GlobeNewswire

6 months ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

ASND

MT Newswires

6 months ago

Ascendis Pharma Unveils $300 Million ADS Offering

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

ASND

GlobeNewswire

6 months ago

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

ASND

Zacks

7 months ago

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

ASND

Zacks

7 months ago

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

ASND

GuruFocus.com

7 months ago

RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

ASND

Investor's Business Daily

7 months ago

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term

ASND

Benzinga

7 months ago

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term

ASND

MT Newswires

7 months ago

Ascendis Pharma Says Trial of Potential Dwarfism Drug Achieved Primary Endpoint

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

ASND

GlobeNewswire

7 months ago

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

ASND

Insider Monkey

7 months ago

Ascendis Pharma A/S (ASND): Among Hedge Funds’ Top Biotech Stock Picks

ASND

MT Newswires

7 months ago

Ascendis Says Initial Data Shows Anti-Tumor Activity in Phase 1/2 Platinum-Resistant Ovarian Cancer Trial

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

ASND

GlobeNewswire

7 months ago

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

ASND

MT Newswires

7 months ago

Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

ASND

GlobeNewswire

7 months ago

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

ASND

Benzinga

7 months ago

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Why Ascendis Pharma Stock Tumbled by 11% Today

ASND

Motley Fool

7 months ago

Why Ascendis Pharma Stock Tumbled by 11% Today

Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut

ASND

Investor's Business Daily

7 months ago

Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut

ASND

MT Newswires

7 months ago

Sector Update: Health Care Stocks Fall Premarket Wednesday

Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout

ASND

Investor's Business Daily

7 months ago

Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout

ASND

MT Newswires

7 months ago

Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement

ASND

MT Newswires

7 months ago

Ascendis Pharma Q2 Loss Narrows, Sales Slump -- Shares Plunge After Hours

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

ASND

GlobeNewswire

7 months ago

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

ASND

GlobeNewswire

7 months ago

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Ascendis Pharma Reports Second Quarter 2024 Financial Results

ASND

GlobeNewswire

7 months ago

Ascendis Pharma Reports Second Quarter 2024 Financial Results

ASND

GuruFocus.com

7 months ago

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Report Preview: What To Expect

ASND

Simply Wall St.

7 months ago

Exploring Three High Growth Tech Stocks In The United States

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

ASND

GlobeNewswire

7 months ago

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

ASND

Zacks

8 months ago

Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath

ASND

Zacks

8 months ago

Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?

FDA approves Ascendis Pharma’s YORVIPATH for hypoparathyroidism

ASND

Pharmaceutical Technology

8 months ago

FDA approves Ascendis Pharma’s YORVIPATH for hypoparathyroidism

Ascendis Pharma Zips Higher After FDA Approves Embattled Drug

ASND

Investor's Business Daily

8 months ago

Ascendis Pharma Zips Higher After FDA Approves Embattled Drug

ASND

MT Newswires

8 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-bell Monday

ASND

MT Newswires

8 months ago

Sector Update: Health Care

ASND

MT Newswires

8 months ago

Ascendis Pharma Gets US FDA Approval of Hypoparathyroidism Therapy

FDA approves Ascendis drug for rare endocrine condition

ASND

BioPharma Dive

8 months ago

FDA approves Ascendis drug for rare endocrine condition

FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults

ASND

GlobeNewswire

8 months ago

FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults

ASND

Simply Wall St.

8 months ago

Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year

2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect

ASND

TipRanks

9 months ago

2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect

ASND

MT Newswires

9 months ago

Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada

Pendopharm and Ascendis to distribute hypoparathyroidism treatment

ASND

Pharmaceutical Technology

9 months ago

Pendopharm and Ascendis to distribute hypoparathyroidism treatment

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada

ASND

CNW Group

9 months ago

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada

ASND

MT Newswires

9 months ago

TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

ASND

GlobeNewswire

9 months ago

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

ASND

Insider Monkey

9 months ago

Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

ASND

GlobeNewswire

10 months ago

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

ASND

MT Newswires

10 months ago

Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

ASND

GlobeNewswire

10 months ago

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

ASND

MT Newswires

10 months ago

Stifel Initiates Ascendis Pharma at Buy Rating With $200 Price Target

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

ASND

GlobeNewswire

10 months ago

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months

ASND

Benzinga

a year ago

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months

ASND

Zacks

a year ago

Latest Ascendis Pharma A/S (ASND) News on April 3, 2025

Share on Social Networks: